Methods of treating cancer

Patent metadata

Field	Value
Publication number	US-12162865-B2
Application number	US-202217689704-A
Country	US
Kind code	B2
Filing date	Mar 8, 2022
Priority date	Oct 15, 2012
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

Abstract

The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

First claim

We claim:

1. A method of treating a human subject comprising administering to the human subject a compound:

or a pharmaceutically acceptable salt thereof;
wherein the human subject has reduced expression or loss of function of INI1 and epithelioid sarcoma.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a hydrobromic acid salt.

3. The method of claim 1 , wherein the human subject has reduced expression of INI1.

4. The method of claim 2 , wherein the human subject has reduced expression of INI1.

5. The method of claim 1 , wherein the human subject has loss of function of INI1.

6. The method of claim 2 , wherein the human subject has loss of function of INI1.

7. The method of claim 3 , wherein reduced expression of INI1 is detected by an immunoassay.

8. The method of claim 4 , wherein reduced expression of INI1 is detected by an immunoassay.

9. The method of claim 5 , wherein loss of function of INI1 is determined by detecting any alteration in a nucleic acid sequence encoding INI1.

10. The method of claim 6 , wherein loss of function of INI1 is determined by detecting any alteration in a nucleic acid sequence encoding INI1.

11. The method of claim 5 , wherein loss of function is caused by a loss of function mutation.

12. The method of claim 6 , wherein loss of function is caused by a loss of function mutation.

13. The method of claim 9 , wherein loss of function is caused by a loss of function mutation.

14. The method of claim 10 , wherein loss of function is caused by a loss of function mutation.

Assignees

• Epizyme Inc

Inventors

• Knutson Sarah K
• Warholic Natalie
• Keilhack Heike

Classifications

• A61K31/4545

  containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title

• A61K31/4412

  having oxo groups directly attached to the heterocyclic ring · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• A61K31/5377 Primary

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• C07D405/12

  linked by a chain containing hetero atoms as chain links · CPC title